ChemoCentryx Inc. | Ownership
Companies that own ChemoCentryx Inc.
BVF Partners LP
7,034,346
14.31%
-166,970
6.25%
06/30/2018
Wasatch Advisors, Inc.
2,378,263
4.84%
-4,669
0.21%
06/30/2018
BlackRock Fund Advisors
2,245,421
4.57%
118,414
0%
06/30/2018
Franklin Advisers, Inc.
1,515,197
3.08%
-172,217
0.01%
06/30/2018
The Vanguard Group, Inc.
1,195,769
2.43%
17,718
0%
06/30/2018
Farallon Capital Management LLC
1,150,000
2.34%
200,000
0.1%
06/30/2018
Carmignac Gestion SA
1,026,137
2.09%
636,040
0.07%
06/30/2018
Carmignac Gestion Luxembourg SA (UK)
1,026,137
2.09%
636,040
0.88%
06/29/2018
Acadian Asset Management LLC
743,298
1.51%
221,434
0.03%
06/30/2018
Renaissance Technologies LLC
719,481
1.46%
-49,800
0.01%
06/30/2018
| Address |
850 Maude Avenue
Mountain View California 94043
United States
|
|
Employees
|
- |
| Website |
http://www.chemocentryx.com |
| Updated |
07/08/2019 |
| ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. |
